ASCO Annual Meeting Coverage
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ASCO Review: Progress Is Where You Find It
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
With New Leadership, Roche Goes Back To Basics At ASCO
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
Latest From ASCO
US FDA’s Project Facilitate Making Some Improvements To Expanded Access
Analysis presented at ASCO concludes that pilot program helped physicians request access to investigational drugs for individual patients. Now agency officials are suggesting an expansion of the project.
Cancer Drug Prices Inconsistent With Value Scores From NCCN Prescribing Tool
Research presented at the American Society for Clinical Oncology annual meeting evaluates cancer drug costs and benefits using two value frameworks meant to assist physicians and patients in treatment decisions.
Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Anti-BCMA Therapies Aim To Raise The Bar In Myeloma
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Next Generation SERDs Progress In Breast Cancer; Standing Out In The Crowd Won't Be Easy
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.
Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
GSK Keeps Oncology 2.0 Growth Plans On Track
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.